A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

被引:83
作者
Butowski, Nicholas [1 ]
Chang, Susan M. [1 ]
Junck, Larry [2 ]
DeAngelis, Lisa M. [3 ]
Abrey, Lauren [3 ]
Fink, Karen [4 ]
Cloughesy, Tim [5 ]
Lamborn, Kathleen R. [1 ]
Salazar, Andres M. [6 ]
Prados, Michael D. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[2] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Baylor Univ, Dallas, TX 75246 USA
[5] Univ Calif Los Angeles, Los Angeles, CA 90095 USA
[6] Oncovir Inc, Washington, DC 20008 USA
关键词
Glioblastoma multiforme; Radiation therapy; Adjuvant therapy; Poly-ICLC; DOUBLE-STRANDED-RNA; POLYINOSINIC-POLYCYTIDYLIC ACID; TOLL-LIKE RECEPTOR-3; PROTEIN-KINASE; L-LYSINE; MALIGNANT GLIOMA; ADJUVANT TEMOZOLOMIDE; SUPPRESSOR FUNCTION; ACTIVATED ENZYMES; CELL CARCINOMA;
D O I
10.1007/s11060-008-9693-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), in combination with and following radiation therapy (RT). Methods and materials This was an open-label, single arm phase II study. Patients were treated with RT in combination with poly-ICLC followed by poly-ICLC as a single agent. Poly-ICLC was initiated 7-28 days after the surgical procedure that established the diagnosis; radiotherapy began within 7 days of the first dose of poly-ICLC and within 35 days of surgical diagnosis. Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression. Results 31 patients were enrolled in this study. One patient did not have a Glioblastoma mutiforme and was deemed ineligible. For the 30 eligible patients, time to progression was known for 27 patients and 3 were censored. The estimated 6-month progression-free survival was 30% and the estimated 1-year progression-free survival was 5%. Median time to progression was as 18 weeks. The 1-year survival was 69% and the median survival was 65 weeks. Conclusions The combined therapy was relatively well-tolerated. This study suggests a survival advantage compared to historical studies using RT without chemotherapy but no survival advantage compared to RT with adjuvant nitrosourea or non-temozolomide chemotherapy. Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 45 条
  • [11] FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO
  • [12] 2-S
  • [13] THE BINDING OF DOUBLE-STRANDED-RNA AND ADENOVIRUS VAI RNA TO THE INTERFERON-INDUCED PROTEIN-KINASE
    GALABRU, J
    KATZE, MG
    ROBERT, N
    HOVANESSIAN, AG
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 178 (03): : 581 - 589
  • [14] Interferon-responsive protein kinase (p68) and proliferating cell nuclear antigen are inversely distributed in head and neck squamous cell carcinoma
    Haines, GK
    Panos, RJ
    Bak, PM
    Brown, T
    Zielinski, M
    Leyland, J
    Radosevich, JA
    [J]. TUMOR BIOLOGY, 1998, 19 (01) : 52 - 59
  • [15] HAWKINS MJ, 1985, J BIOL RESP MODIF, V4, P664
  • [16] INTERFERON-INDUCED AND DOUBLE-STRANDED RNA-ACTIVATED ENZYMES - A SPECIFIC PROTEIN-KINASE AND 2',5'-OLIGOADENYLATE SYNTHETASES
    HOVANESSIAN, AG
    [J]. JOURNAL OF INTERFERON RESEARCH, 1991, 11 (04): : 199 - 205
  • [17] On the discovery of interferon-inducible, double-stranded RNA activated enzymes: The 2'-5'oligoadenylate synthetases and the protein kinase PKR
    Hovanessian, Ara G.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2007, 18 (5-6) : 351 - 361
  • [18] HUBBELL HR, 1984, CANCER RES, V44, P3252
  • [19] Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes
    Kim, Hyemi
    Yang, Eunjung
    Lee, Jeonggi
    Kim, Se-Hoon
    Shin, Jeon-Soo
    Park, Joo Young
    Choi, Sun Ju
    Kim, Se Jong
    Choi, In-Hong
    [J]. IMMUNOLOGY, 2008, 124 (04) : 480 - 488
  • [20] KROWN SE, 1985, J BIOL RESP MODIF, V4, P640